More importantly, Inhibiting TRPM2 can significantly enhance the cytotoxic effects of chemotherapy drugs in triple-negative (TN) and estrogen receptor-positive (ER+) breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.